NetworkNewsBreaks – Nemaura Medical Inc. (NASDAQ
Post# of 73
(Total Views: 234)
Posted On: 02/11/2022 3:00:17 PM
NetworkNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Appoints New COO in Readiness for Manufacturing and Distribution Scale-Up, Commercialization Phase of Growth
Nemaura Medical (NASDAQ: NMRD) recently appointed Dr. Arash Ghadar as its chief operating officer. Dr. Ghadar brings decades of health care and technical experience to Nemaura, including from his previous role as technical director at Datalink Electronics and his current director role at Medilink Midlands. “Ash will play an important role at Nemaura as we begin to scale up our manufacturing and distribution operations… He brings over 20 years of product development, management and leadership experience spanning both business and technical disciplines. His main area of expertise is in the medical devices sector, and primarily within a contract design and manufacturing setting. That will be a true asset for the company during the commercialization phase of our growth,” a recent article quotes Nemaura CEO Dr. Faz Chowdhury as saying. The company is currently commercializing its sugarBEAT(R) non-invasive, flexible and affordable continuous glucose monitoring (“CGM”) device in the U.K. NMRD also recently launched beta trials of Miboko, its new metabolic health program for use by employers and insurers worldwide, which has started to gain significant traction.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Nemaura Medical (NASDAQ: NMRD) recently appointed Dr. Arash Ghadar as its chief operating officer. Dr. Ghadar brings decades of health care and technical experience to Nemaura, including from his previous role as technical director at Datalink Electronics and his current director role at Medilink Midlands. “Ash will play an important role at Nemaura as we begin to scale up our manufacturing and distribution operations… He brings over 20 years of product development, management and leadership experience spanning both business and technical disciplines. His main area of expertise is in the medical devices sector, and primarily within a contract design and manufacturing setting. That will be a true asset for the company during the commercialization phase of our growth,” a recent article quotes Nemaura CEO Dr. Faz Chowdhury as saying. The company is currently commercializing its sugarBEAT(R) non-invasive, flexible and affordable continuous glucose monitoring (“CGM”) device in the U.K. NMRD also recently launched beta trials of Miboko, its new metabolic health program for use by employers and insurers worldwide, which has started to gain significant traction.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)